Pembrolizumab-vibostolimab for previously untreated non-small-cell lung cancer (NSCLC)

Pembrolizumab-vibostolimab is in development for treatment-naïve patients with metastatic non-small cell lung cancer (NSCLC). A metastatic NSCLC is an advanced stage of NSCLC (stage 4), where the cancer has spread from the lungs. NSCLC is the most common form of lung cancer, accounting for about 80 to 85 out of every 100 lung cancer cases. Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide. Several risk factors have been linked to lung cancer, including smoking, inhalation of radon, and exposure to certain chemicals. The main symptoms of lung cancer are chest infections, long-standing cough and coughing up blood, persistent breathlessness, pain when breathing or coughing, and unexplained weight loss. Most patients acquire resistance to existing treatment options over time. As vibostolimab affects immunoreceptors, the combination of pembrolizumab and vibostolimab may decrease such resistance and improve clinical outcomes.